AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).
Swiss cancer giant Novartis (NOVN: VX) has entered into an exclusive worldwide licensing and collaboration deal with Ratio ...
New York-based ophthalmic technology company Eyenovia is considering its options. Shares in the company dropped by 70% on ...
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to ...
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...
New research published by the European Federation of Industries and Associations (EFPIA) provides in-depth analysis of the ...
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from ...
Denmark's health reform targets chronic disease care, health inequalities, and innovation, with measures like chronic care ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...
Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback